The Government of India has approved Skymap Pharmaceuticals Private Limited as the strategic buyer for the 100% disinvestment of Indian Medicines Pharmaceutical Corporation Limited. The Roorkee based company emerged as the highest bidder with an offer of approximately ₹121.01 crore for the profit making public sector enterprise. This transaction marks the first successful strategic disinvestment of a central public sector entity for the 2026-27 financial year.
Details of the Strategic Sale
The strategic sale of Indian Medicines Pharmaceutical Corporation Limited (IMPCL) involves the transfer of 100% equity shareholding and complete management control to Skymap Pharmaceuticals Private Limited. The Government of India holds 98.11% of the company, while the remaining 1.89% is owned by Kumaon Mandal Vikas Nigam Limited (KMVNL), a public sector undertaking of the Uttarakhand government. The winning bid of ₹121.01 crore (specifically ₹121,00,94,400) was cleared by the Alternative Mechanism, an empowered group of ministers including the Finance Minister and the Minister for Road Transport and Highways.
This disinvestment process was managed by the Department of Investment and Public Asset Management (DIPAM) under the Ministry of Finance. The move follows the “in-principle” approval granted by the Cabinet Committee on Economic Affairs (CCEA) in November 2017. Skymap Pharmaceuticals was declared the winner after a competitive bidding process where two sealed financial bids were evaluated against a reserve price set by the government.
About Indian Medicines Pharmaceutical Corporation Limited (IMPCL)
Established on July 12, 1978, IMPCL is a Mini Ratna Category-II public sector enterprise under the administrative control of the Ministry of Ayush. The company is headquartered at Mohan in the Almora district of Uttarakhand. It is uniquely positioned as the only government owned facility in India that manufactures both Ayurvedic and Unani medicines on a large scale.
The company manufactures over 650 classical Ayurvedic formulations and approximately 330 Unani medicines. It also produces dozens of proprietary medicines. IMPCL has been a critical supplier for the National Ayush Mission (NAM), the Central Government Health Scheme (CGHS), and more than 6,000 Jan Aushadhi Kendras across the country. Financially, it has remained a consistently profitable entity, reporting a net profit of ₹17.65 crore on a turnover of ₹177.31 crore in the 2024-25 financial year.
Profile of Skymap Pharmaceuticals Private Limited
The strategic buyer, Skymap Pharmaceuticals Private Limited, is a prominent Indian pharmaceutical company established on June 24, 2006. Based in Roorkee, Uttarakhand, the company operates a highly automated, EU GMP approved manufacturing facility. Skymap specializes in a wide range of medical formulations, including injections, oral solids like tablets and capsules, and ophthalmic products.
The company has a significant domestic presence and is also a major exporter, reaching markets in the European Union (EU), Asia, and Latin America. By acquiring IMPCL, Skymap is expected to leverage its modern manufacturing expertise to scale up the production of traditional Ayurvedic and Unani medicines. This transition is seen as a way to bring private sector efficiency and advanced technology into the production of standardized Ayush products.
Significance of the Disinvestment
The privatization of IMPCL is a significant step in the government’s broader strategy of asset monetization and focusing on strategic sectors. Although IMPCL has been a profitable unit, the strategic sale aims to unlock its full potential by integrating it with private sector logistics, marketing, and research capabilities. This is particularly important for the Ayush sector, where standardization and global competitiveness are key goals of the Ministry of Ayush.
The location of the IMPCL factory in the Kumaon region of Uttarakhand makes it a vital economic hub for the local community. The factory supports numerous small scale industries and thousands of local farmers who supply raw materials such as herbal extracts and medicinal plants. The strategic buyer is expected to maintain and expand these local linkages while modernizing the production facility to meet international quality standards for traditional medicines.
Key Takeaways
- Skymap Pharmaceuticals Private Limited has been approved as the strategic buyer for the 100% disinvestment of Indian Medicines Pharmaceutical Corporation Limited (IMPCL).
- The winning bid for the strategic sale was ₹121.01 crore, which involves the transfer of both equity and management control to the private buyer.
- IMPCL was established in July 1978 and is a Mini Ratna Category-II central public sector enterprise under the Ministry of Ayush.
- The company is headquartered in Mohan, Almora (Uttarakhand), and is known for manufacturing over 980 classical Ayurvedic and Unani medicines.
- The disinvestment process was overseen by the Department of Investment and Public Asset Management (DIPAM) under the Ministry of Finance.
- This transaction marks the first successful strategic disinvestment of a public sector entity in India for the 2026-27 financial year.
